Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings Inc (RANI) is a clinical-stage biotherapeutics leader developing oral alternatives to injectable biologic medications through its patented RaniPill technology. This page provides investors and industry observers with timely updates on corporate milestones, clinical trial progress, and strategic initiatives shaping the future of non-invasive drug administration.
Access official press releases, financial disclosures, and third-party analysis covering RANI's advancements in transforming treatments for chronic diseases. Key updates include trial results for oral biologic formulations, intellectual property developments, partnership announcements with pharmaceutical collaborators, and quarterly performance reports.
Bookmark this page for streamlined tracking of RANI's progress in addressing critical challenges in drug delivery. Return regularly to monitor how the company's capsule-based technology could impact treatment adherence, patient comfort, and the broader $500B+ biologics market.
Rani Therapeutics announced positive topline results from its Phase 1 trial of RT-102, a treatment for osteoporosis, demonstrating high oral bioavailability and successful drug delivery. The company completed a debt financing agreement of up to $45 million, ensuring operations are funded into mid-2024. Rani plans to initiate a third Phase 1 clinical trial and expects topline results from the repeat-dose portion of RT-102 by Q4 2022. As of June 30, 2022, cash and equivalents were $97.2 million, while R&D expenses rose significantly year-over-year to $9.5 million.
Rani Therapeutics announced positive topline results from its Phase 1 clinical study of RT-102, an oral capsule with human parathyroid hormone (PTH) analog for osteoporosis treatment. The study demonstrated that RT-102 was well-tolerated, with a 95% drug delivery success rate and a bioavailability of 300-400% greater than subcutaneous injections. The company aims to file an IND for Phase 2 trials by Q3 2023, building on the success of RT-101 and further validating the RaniPill platform.
Rani Therapeutics (RANI) reported its Q1 2022 financial results, highlighting the initiation of a Phase 1 trial for RT-102, aimed at treating osteoporosis. The company unveiled the RaniPill HC, which can deliver more than 20 mg of therapeutic payloads, enhancing its pipeline potential. Rani's cash position stood at $107.8 million, sufficient for operations through 2023. R&D expenses increased to $7.6 million, while general and administrative expenses rose to $6.2 million. The net loss for the quarter was $13.8 million, up from $5.6 million in Q1 2021.
SAN JOSE, Calif., May 3, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics, a clinical-stage biotherapeutics company, announced that CEO Talat Imran will present at two investment conferences in May. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 5:20 PM PT, while the H.C. Wainwright Annual Global Life Sciences Conference will take place on May 24 at 10:30 AM PT. Interested participants can access the live webcasts on Rani's Investor Relations page, with replays available for 90 days post-presentation.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has been recognized by Fast Company with the top honor in the Health category of the 2022 World Changing Ideas Awards for its RaniPill™ capsule. This innovative technology aims to replace painful injections for biologic drugs, facilitating oral delivery while maintaining high bioavailability. The capsule, which contains a dissolvable needle, is currently undergoing multiple clinical trials, with the company striving to be a leader in oral biologics across various therapeutic areas.
Rani Therapeutics Holdings (Nasdaq: RANI) announced that CEO Talat Imran will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET. This event provides an opportunity for investors and interested parties to hear insights directly from Rani's leadership.
Participants can access the live audio webcast through Needham or the Investor Relations section of Rani's website. A replay will be available for 90 days after the event.
Rani Therapeutics has initiated a Phase 1 clinical trial of RT-102, an oral treatment for osteoporosis. The company launched the RaniPill™ High Capacity (HC), enhancing delivery capacity to over 20 mg. Financially, cash reserves rose to $117.5 million in 2021, supporting operations through 2023. R&D expenses surged to $26.5 million due to increased headcount and equity compensation. However, net losses also expanded to $53.1 million. The company anticipates topline Phase 1 data in 2H 2022 and plans further clinical trials.
Rani Therapeutics (Nasdaq: RANI) will announce its fourth quarter and full year 2021 financial results on March 29, 2022, after market close. A conference call to discuss these results will take place at 1:30 p.m. PT / 4:30 p.m. ET that same day. Rani Therapeutics focuses on the oral delivery of biologics, having developed the RaniPill™ capsule aimed at replacing subcutaneous injections. The company has conducted various preclinical and clinical studies to assess the safety and bioavailability of the RaniPill™ technology.
Rani Therapeutics (Nasdaq: RANI) announced the initiation of a Phase 1 study for RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) aimed at treating osteoporosis. This study is critical as it utilizes the RaniPill™ capsule to deliver PTH orally, potentially improving patient adherence compared to daily self-injections. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of RT-102 in healthy adult women. Rani aims to revolutionize the delivery of biologics with this innovative oral treatment.
Rani Therapeutics has announced the development of RaniPill™ HC, a high-capacity oral delivery device capable of delivering over 500% more biologic payload than its existing capsule. This device can potentially deliver up to 20mg of biologics, unlocking over 50 new drug opportunities. In preliminary financial results, the company estimates a net loss of $13-15 million for Q4 2021, up from $5.8 million in Q4 2020, and a full-year loss between $53-55 million, compared to $16.7 million in 2020. Cash reserves are approximately $117.5 million.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
